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SUMMARY
Objective: To investigate the association between non-alcoholic fatty liver disease 
(NAFLD) and liver function/injury markers with components of metabolic syndrome 
(MS) in class III obese individuals. Methods: The study population consisted of 144 
patients with class III obesity (body mass index [BMI] ≥ 40 kg/ m²). MS was diagnosed 
according to the National Cholesterol Education Program – Adult Treatment Panel III 
(NCEP ATP III)  criteria, by determining the lipid profile, blood glucose, and basal insulin. 
Liver function/injury markers were also quantified. Insulin resistance (IR) was measured 
by HOMA-IR and NAFLD diagnosis was established by magnetic resonance imaging 
(MRI). Statistical calculations were performed by SPSS version 13.0. The association was 
assessed by the Mann-Whitney and Chi-square tests, with a level of significance set at 5%. 
Results: There was a significant association between the diagnosis of MS and NAFLD 
(χ2 = 6.84, p = 0.01). As for the diagnostic components of MS, there was a positive and 
significant association between HDL-C (p = 0.05), waist circumference (p < 0.05), and 
hypertension (χ2 = 4.195, p = 0.041) with NAFLD. HOMA-IR (p < 0.001) also showed a 
positive association with liver disease. Conclusion: A positive and significant association 
between NAFLD and components of metabolic syndrome in class III obese individuals 
was observed, suggesting the need and importance of monitoring these components in 
NAFLD screening.
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INTRODUCTION
The non-alcoholic fatty liver disease (NAFLD) is charac-
terized by accumulation of fat in the liver when it exceeds 
5-10% of its weight1. In addition to leading to major histo-
pathological alterations, it may be associated with elevated 
liver enzymes and abnormal liver function, ranging from 
steatosis to steatohepatitis, fibrosis, and cirrhosis2. 
Although diagnosed worldwide, there are variations in 
prevalence, reaching about 20-30% in western countries3. 
In the United States, where 25% of the adult population is 
obese, the disease occurs in more than two-thirds of these 
individuals and in more than 90% of class III obese indi-
viduals4. It is estimated that 2% to 3% of the population has 
nonalcoholic steatohepatitis (NASH)3.
Approximately 74% to 90% of patients who undergo 
liver biopsy show alterations due to triacylglycerol ac-
cumulation2,5. The disease is highly prevalent (88.7%) in 
obese patients undergoing bariatric surgery6, and the like-
lihood of developing steatohepatitis is increased in class 
III obesity, with 15% to 20% of these patients diagnosed 
with NASH7.  
Recent studies have shown increased prevalence and 
higher incidence of cardiovascular disease (CVD) in in-
dividuals with NAFLD. These studies have shown hepatic 
steatosis as an independent risk factor for the development 
of this disease8,9.
Metabolic syndrome (MS), which involves the combi-
nation of risk factors for CVD such as insulin resistance 
(IR), abdominal fat, dyslipidemia, glucose intolerance, and 
hypertension, has often been associated with more severe 
liver abnormalities10. 
OBJECTIVE
To investigate the association between NAFLD and liver 
function/injury markers with the components of MS in in-
dividuals with class III obesity treated at a private clinic in 
the city of Rio de Janeiro, Brazil. 
METHODS
The study included 144 individuals with class III obesity, 
of both genders, with a mean age of 36.5 (11.7) years, 
from a private clinic in the city of Rio de Janeiro in the 
period from January to December 2006, representing ap-
proximately 60% of the total annual attendance. Pregnant 
women, nursing mothers, individuals with liver disease 
other than NAFLD (positive serology for hepatitis B and 
C), with daily intake of more than 20 grams of ethanol, 
and those using hepatotoxic drugs were excluded from the 
study.  NAFLD diagnosis was achieved by magnetic reso-
nance imaging assessment. 
The class III obesity classification was based on the 
World Health Organization (WHO) criteria (1998)11, 
defined by body mass index (BMI) ≥ 40 kg/m² for the 
diagnosis of this class of obesity. BMI calculation was per-
formed using the anthropometric measurements weight 
(kg) and height (m²)12. Blood pressure (BP) and waist cir-
cumference (WC) were also measured. WC was measured 
with the patient standing with the abdomen relaxed, arms 
at the sides of the body and feet side by side, using an inex-
tensible tape. The tape surrounded the individual’s largest 
abdominal sagittal diameter, as individuals with class III 
obesity have what is called an abdominal “apron”13. 
For biochemical evaluation, a blood sample was ob-
tained by venipuncture, after a 12-hour fast. The lipid pro-
file, blood glucose, and basal insulin levels were evaluated. 
Basal insulin was quantified by reversed phase high per-
formance liquid chromatography (RP-HPLC). Addition-
ally, the following markers of liver function (albumin, total 
bilirubin [TB] and activated prothrombin time [APT] – 
the latter described in seconds above the control) and liver 
injury (aspartate aminotransferase [AST], alanine amino-
transferase [ALT], and gamma glutamyl transpeptidase 
[GGT]) were evaluated. 
IR was identified by HOMA-IR14, obtained by the for-
mula: HOMA-IR = fasting insulin (mU/L) × fasting glu-
cose (mmol/L)/22.5. The receiver operating characteris-
tic curve (ROC) was used for the identification of IR. To 
determine the gold standard for implementing the ROC 
curve, with subsequent identification of the value of high-
est IR sensitivity and specificity in this sample, reference 
values  in the literature for healthy adult subjects were 
used15-18, thus obtaining a value > 4.0 as cutoff point.
The diagnosis of MS was performed according to the 
National Cholesterol Education Program – Adult Treat-
ment Panel III19 (NCEP - ATP III), which defines MS by 
the presence of at least three of the following components: 
WC  ≥  102 cm in men and ≥ 88 cm in women, HDL-c 
≤ 40 mg/dL in men and ≤ 50 mg / dL in women, triglyc-
erides ≥ 150 mg/dL, fasting glucose ≥ 110 mg / dL, and 
blood pressure ≥ 130/85 mmHg. 
Statistical calculations were carried out using SPSS, re-
lease 13.0. The comparison of numerical and continuous 
variables (age, WC, lipid profile, blood glucose, insulin, 
and liver function/injury tests) between groups with and 
without NAFLD was performed by the Mann-Whitney 
test. Associations between categorical variables (presence 
or absence of hypertension (SAH), NAFLD, IR and MS) 
were performed using the chi-square (χ2) test. The coef-
ficient of the proportion was performed to measure the 
degree of association between the categorical variables 
NAFLD and metabolic syndrome. The ROC curve was 
used to identify the most accurate value of HOMA-IR to 
diagnose IR. The significance level was set at 5%. 
This study was approved by the Ethics Committee in 
Research of the Hospital Universitário Clementino Fraga 
Filho, Universidade Federal do Rio de Janeiro. 
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  Presence of MS Absence of MS
p-value r2 Coefﬁcient of contingency
  n % n %
Presence of NAFLD 57 81.4 45 61.6      
      0.01 6.84 0.21
Absence of NAFLD 13 18.6 29 38.4      
NAFLD, non-alcoholic fatty liver disease; MS, metabolic syndrome.
Table 1 – Association between the presence of NAFLD and diagnosis of MS





Absence of NAFLD  
(n = 42) p-value
Mean (SD) Mean (SD)
WC (cm) 126.5 (15) 121.9 (11.6) 0.050
AST (U/L) 25.9 (10.2) 22.4 (14.3) 0.003
ALT (U/L)  36.5 (21.1) 27.9 (19.1) 0.003
Bilirubin (mg/dL) 0.56 (0.22) 0.58 (0.22) 0.585
GGT (U/L) 40.9 (29.8) 45.1 (65.8) 0.452
Albumin (g/dL) 4.4 (3.5) 4.0 (0.4) 0.869
APT 0.24 (0.59) 0.31(0.39) 0.042
Total cholesterol (mg/dL) 201.4 (41.8) 193.7 (28.0) 0.488
Triglycerides (mg/dL) 151.2 (76.0) 134.3 (66.5) 0.149
HDL-c (mg/dL) 45.9 (11.20) 49.1 (8.8) 0.050
LDL-c (mg/dL) 122.1 (38.5) 113.6 (37.5) 0.578
Basal glycemia (mg/dL) 100.3 (25.4) 95.8 (23.9) 0.132
Basal insulin (μU/mL) 20.59 (13.26) 18.57 (12.27) 0.141
HOMA-IR 4.4 (2.4) 2.4 (0.9) 0.000
SD, standard deviation; NAFLD, non-alcoholic fatty liver disease; WC, waist circumference; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; GGT, gamma glutamyl transpeptidase; APT, seconds above the control.
RESULTS
The sample consisted of 144 subjects, of which 43 (29.4%) 
were males and 101 (70.6%) were females. The mean age of 
subjects was 36.5 (11.7) years, ranging from 19 to 64 years.
There was no significant difference between the mean 
age (p = 0.08) and BMI (p = 0.16) according to gender. 
The prevalence of NAFLD in the study group was 71% 
with a positive diagnosis in 75.0% and 69.3% of men and 
women, respectively.
Of the 144 class III obese patients studied 49% had 
metabolic syndrome, and 81.4% of those with NAFLD 
also had the diagnosis of MS, showing a significant as-
sociation between MS and NAFLD (p = 0.01) (Table 1). 
Table 2 shows a comparative analysis between the groups 
with and without a diagnosis of NAFLD. The mean HDL-c 
was significantly lower in patients with NAFLD. Regard-
ing the anthropometric component of MS, the mean 
WC was significantly higher in subjects diagnosed with 
NAFLD. The means of AST and ALT levels were sig-
nificantly higher, and the APT means were significantly 
lower in this group. Considering the markers of liver 
function and injury in individuals with or without a di-
agnosis of MS, significantly higher means of liver injury 
markers, ALT and GGT, were observed in subjects who 
had MS (Table 3). 
When association tests for categorical variables were 
applied, the only component of the lipid profile that was 
associated with NAFLD was HDL-c, which was below 
the amount considered adequate by the NCEP-ATP III in 
83.0% of patients with liver disease (p = 0.047, χ2 = 4.13).
When analyzing the HOMA-IR, it was observed that 
75.5% of subjects had insulin resistance according to this 
parameter, with only 15% of individuals not presenting 
the disease (p < 0.001, χ2 = 5.641). Furthermore, patients 
with NAFLD had a significantly higher mean of this 
index.
Finally, systemic arterial hypertension (SAH) was 
also associated with the presence of NAFLD (p = 0.041, 
χ2 = 4.195), with 57% of individuals who had a diagnosis 
of liver disease also having SAH.
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Variables
Presence of MS  (n = 70) Absence of MS (n = 74)    
p-value
Mean (SD) Mean (SD) 
AST (U/L) 26.2 (11.1) 23.6 (12.0) 0.112
ALT (U/L) 37.7 (23.03) 30.4 (18.1) 0.022
Bilirubin (mg/dL) 0.56 (0.20) 0.56 (0.24) 0.579
GGT (U/L) 46.1 (33.03) 38.5 (50.94) 0.006
Albumin (g/dL) 4.6 (4.3) 4.0 (0.35) 0.242
APT 0.26 (0.44) 0.30 (0.28) 0.057
SD, standard deviation; MS, metabolic syndrome; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl 
transpeptidase; APT, seconds above the control.
Table 3 – Comparison between the means (SD) of the biochemical variables of liver function/injury between individuals with 
and without MS
DISCUSSION
MS was diagnosed in 81.4% of individuals affected by 
NAFLD. This association confirms the findings by Ferreira 
et al.20 and Soler et al.21, who found a higher prevalence of 
MS in individuals with NAFLD. The growing recognition 
of the association between NAFLD and MS has been stim-
ulating the interest in the possible role of this liver disease 
in the risk for the development of cardiovascular disease22. 
The diagnostic criteria of MS that were associated with 
NAFLD were WC, HDL-c, and blood pressure. Bitencourt 
et al.6 showed a similar trend when evaluating the clinical 
and histological features of NAFLD in obese patients un-
dergoing bariatric surgery, in which more than 50% of the 
cases had diagnostic criteria for MS. 
Several studies have shown that the accumulation of 
body fat in the abdominal region, regardless of the indi-
vidual’s total body fat content, is an independent predic-
tive factor for fat accumulation in hepatocytes and, there-
fore, crucial in the pathogenesis of NAFLD23,24. The WC is 
considered more sensitive to metabolic alterations and/or 
cardiovascular morbimortality than the simple increase in 
body weight measured by BMI21.
In the present study, the mean WC was significantly 
higher in the group with the disease. This association is ex-
plained by the lipolytic nature of visceral fat, due to lower 
insulin sensitivity and higher concentration of β-receptors 
in this region, and its proximity to the portal system25. Vis-
ceral fat is drained directly into the portal system, expos-
ing the liver to large amounts of free fatty acids, which in-
creases the hepatic synthesis of triglycerides and may also 
decrease its ability to secrete them, resulting in accumula-
tion in hepatocytes26. 
The importance of monitoring the WC in individuals 
with NAFLD was described in the study by Yoo27, which 
suggested that this component can be used in the screen-
ing of NAFLD in Korean adults by means of specific values 
for the screening of the disease. 
The only lipid fraction and diagnostic factor of MS 
that was associated with the presence of the disease was 
HDL-c, which showed a significantly lower mean in sub-
jects with NAFLD. Generally, hypertriglyceridemia and 
low HDL-c are the lipid fraction disorders most often as-
sociated with the presence of steatosis28. Boza et al.29 ob-
served significantly lower mean HDL-c levels in class III 
obese individuals with NAFLD, when compared with the 
group without the disease, which is the only lipid fraction 
variable that was associated with NAFLD diagnosis. In the 
study by Dixon et al.30, which evaluated possible predic-
tors of NAFLD in these individuals, no correlation was 
observed between any lipid fraction with more advanced 
stages of the disease. However, a weak negative correlation 
was observed between levels of HDL-c and the degree of 
simple steatosis, graded according to the lobular paren-
chyma involvement. The authors suggest that dyslipidemia 
may have a greater impact on the disease in class I or class 
II obesity and a lower influence in class III. 
Marchesini et al.31, who studied the components of 
MS in 304 individuals with NAFLD, found that over 90% 
of patients with some degree of liver disease have at least 
one component of this syndrome, with approximately one 
third of individuals having all components. Moreover, they 
observed a higher prevalence of disease in diabetic indi-
viduals, being associated to 20% to 75% of cases. However, 
this prevalence seems to be more related to the IR than to 
the hyperglycemia.
In the present study, a significant association between 
IR, as indicated by the HOMA-IR, and the presence of 
NAFLD was observed. Probably due to the accumulation 
of abdominal fat, metabolic abnormalities such as these 
are very prevalent in these individuals21, which is in agree-
ment with studies that suggest that NAFLD is a compo-
nent of MS, associated with visceral adiposity and IR23,32. 
IR, both in the liver and adipose tissue, has been 
strongly associated with NAFLD33,34, as IR has been shown 
to increase with disease severity35. Compared with control 
subjects, individuals with NAFLD have fatty acid oxida-
tion inhibition, shown as decrease in glucose uptake and 
use as fuel, which suggests the possibility that IR may be an 
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intrinsic defect of the disease and the lower response to in-
sulin in adipocytes stimulates tissue lipolysis, contributing 
to the progressive accumulation of lipids in hepatocytes 
through an increased flow of free fatty acids in the liver36. 
The storage of lipids can reach toxic levels and exacerbate 
the production of reactive oxygen species in the liver, 
stimulating the proliferation of macrophages and TNF-α, 
which also interfere with insulin sensitivity37. Thus, abnor-
mal lipid peroxidation results in direct liver damage, with 
inflammation and even fibrosis21.  
A limitation of the present study was the method used 
to assess IR. The hyperinsulinemic euglycemic clamp tech-
nique is considered the gold standard for IR evaluation, as 
it allows the evaluation of insulin sensitivity in both liver 
and peripheral tissues. However, this method is not very 
practical and it is high-cost to be used in population-based 
studies or in clinical practice38. To date, there is no IR labo-
ratory method that can meet all of the following criteria for 
universal acceptance and use: sufficiently precise measures 
so that IR can be compared between individuals, measures 
that can be obtained independently from the glucose from 
which it is obtained, data collection within the physiologi-
cal range of insulin action and low cost and possibility of 
use in clinical practice. 
HOMA is a simple and low cost method for the evalu-
ation of IR but it has some limitations. In this model, IR 
measurement is performed for total body surface, con-
sidering that insulin sensitivity would be the same in the 
liver and peripheral tissues. There is some criticism re-
garding the specificity of the techniques used to evaluate 
basal insulin, which can be corrected by using specific and 
standardized methodologies that do not suffer influence 
of pro-insulin levels. The proportionality between insu-
linemia and the degree of IR is also debatable39. Despite its 
limitations, this has been the method most often used to 
assess insulin resistance in population studies.
Liver damage can be identified through liver damage 
markers: AST, ALT, and GGT. In the present study, the 
means of AST and ALT, although within the reference 
values,  were significantly higher in those with NAFLD. 
Furthermore, higher mean levels of ALT and GGT were 
observed in individuals with MS. 
The present study did not assess the severity of NAFLD, 
which can justify the fact that no difference was found in 
the means of the other liver functions and injury tests in 
individuals with and without MS, as well as explain the fact 
that the mean values  of liver function tests are within the 
normal range in the group with the disease, as more severe 
alterations at liver function and injury tests are observed 
only in individuals with advanced liver disease. However, 
data published in the “Third national health and nutrition 
survey” showed a significant association between high 
concentrations of ALT and insulin resistance, diabetes 
mellitus type 2, and MS40. Moreover, Koller et al.41 suggest-
ed that the markers of liver injury may be indicators for the 
screening of individuals with MS or its components. How-
ever, further studies should be performed to determine the 
association between MS and NAFLD severity. 
CONCLUSION
In the present study, the association between the diag-
nosis of NAFLD and MS was observed. MS components 
cause metabolic alterations, such as insulin resistance and 
oxidative stress that may contribute to the progression and 
worsening of liver disease. Therefore, the determination 
and monitoring of these components are of crucial impor-
tance for the screening of NAFLD.
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